1454846-35-5 | Pf-06463922

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$16.00	$11.00
5mg	98%	in stock	$28.00	$20.00
25mg	98%	in stock	$60.00	$42.00
100mg	98%	in stock	$83.00	$58.00
250mg	98%	in stock	$159.00	$111.00
1g	98%	in stock	$504.00	$353.00

Description

• Catalog Number: AA63428
• Chemical Name: Pf-06463922
• CAS Number: 1454846-35-5
• Molecular Formula: C21H19FN6O2
• Molecular Weight: 406.413
• MDL Number: MFCD28144520
• SMILES: N#Cc1n(C)nc2c1-c1cnc(c(c1)O[C@H](C)c1c(C(=O)N(C2)C)ccc(c1)F)N

Computed Properties

• Complexity: 700
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• XLogP3: 1.5

Literature

• Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

  Translational lung cancer research 20160601

• Resistance: Crizotinib makes a comeback.

  Nature reviews. Cancer 20160201

• Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

  The New England journal of medicine 20160107

• PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

  Proceedings of the National Academy of Sciences of the United States of America 20150317

• Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

  Journal of medicinal chemistry 20140612